{"id":"NCT00064077","sponsor":"Gynecologic Oncology Group","briefTitle":"Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix","officialTitle":"A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-05","primaryCompletion":"2011-01","completion":"2018-01-30","firstPosted":"2003-07-09","resultsPosted":"2018-08-28","lastUpdate":"2018-10-17"},"enrollment":513,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma","Recurrent Cervical Carcinoma","Stage IVB Cervical Cancer"],"interventions":[{"type":"DRUG","name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"type":"DRUG","name":"Gemcitabine Hydrochloride","otherNames":["dFdCyd","Difluorodeoxycytidine Hydrochloride","Gemzar","LY-188011"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"]},{"type":"OTHER","name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"type":"DRUG","name":"Topotecan Hydrochloride","otherNames":["Hycamptamine","Hycamtin","SKF S-104864-A","Topotecan HCl","topotecan hydrochloride (oral)"]},{"type":"DRUG","name":"Vinorelbine Tartrate","otherNames":["Biovelbin","Eunades","KW-2307","Navelbine","Navelbine Ditartrate","NVB","Vinorelbine Ditartrate"]}],"arms":[{"label":"Arm I (paclitaxel, cisplatin)","type":"EXPERIMENTAL"},{"label":"Arm II (vinorelbine, cisplatin)","type":"EXPERIMENTAL"},{"label":"Arm III (gemcitabine, cisplatin)","type":"EXPERIMENTAL"},{"label":"Arm IV (topotecan, cisplatin)","type":"EXPERIMENTAL"}],"summary":"This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating cervical cancer.","primaryOutcome":{"measure":"Duration of Overall Survival (OS)","timeFrame":"Baseline, every other cycle during treatment, then every 3 months for 2 years, the every 6 months for 3 years (up to 5 years)","effectByArm":[{"arm":"Arm I (Paclitaxel, Cisplatin)","deltaMin":12.87,"sd":null},{"arm":"Arm II (Vinorelbine, Cisplatin)","deltaMin":9.99,"sd":null},{"arm":"Arm III (Gemcitabine, Cisplatin)","deltaMin":10.28,"sd":null},{"arm":"Arm IV (Topotecan, Cisplatin)","deltaMin":10.25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":23,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":103},"commonTop":["Anemia","Leukopenia","Neutropenia","Fatigue","Other Gastrointestinal"]}}